RxDoctor Payments Data

Theodore Sawchuk, MD

Urology · Fargo, NDNPI 1629090261

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $3,413 of the $4,407 with a category attached, or 77.5%. Neotract Inc. accounts for 85.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $3,855 and has fallen 99.6% since, to $15 in 2024. Among urology clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,407in general payments, 2019–2025

Across 26 payments — averaging $169.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$4K
  • Teleflex LLC$406
  • Blue Earth Diagnostics$73
  • Coloplast$68
  • Progenics Pharmaceuticals, Inc.$64
  • AbbVie$19
  • plus $31 from 2 others

What the payments were for

  • Travel & lodging$3,41377%
  • Food & beverage$99423%

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,407 in reported general payments places this provider in the 90th percentile of 23 urology providers in North Dakota.

See all urology providers in North Dakota

Medicare billing

Part B allowed, 2024
$101,278
Medicare patients
384
Services billed
1,868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron106$74,365
Tamsulosin Hcl785$14,489
Finasteride531$8,067
Oxybutynin Chloride ErOxybutynin Chloride170$3,622
RenacidinCitric Ac/Gluconolact/Mag Carb16$3,033
Estradiol19$1,317
Dutasteride26$999
Doxazosin Mesylate37$713
Cephalexin229$448
Terazosin Hcl22$434
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst40$382
Oxybutynin Chloride13$283
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim29$182
Alfuzosin Hcl ErAlfuzosin Hcl19$149
Ketorolac Tromethamine12$120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$16$74,365106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 23 urology providers in North Dakota.

Other urology in Fargo

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →